HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stephen Fawell Selected Research

Everolimus

8/2016Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
2/2015Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stephen Fawell Research Topics

Disease

22Neoplasms (Cancer)
11/2023 - 10/2006
4Breast Neoplasms (Breast Cancer)
12/2020 - 02/2015
2Melanoma (Melanoma, Malignant)
01/2016 - 07/2013
1Glioma (Gliomas)
11/2023
1Brain Neoplasms (Brain Tumor)
11/2023
1DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes)
11/2022
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2020
1Hypertension (High Blood Pressure)
01/2020
1Sarcoma (Soft Tissue Sarcoma)
01/2020
1Disease Progression
01/2020
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
01/2020
1B-Cell Lymphoma (Lymphoma, B Cell)
11/2018
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
11/2018
1Adenoid Cystic Carcinoma (Cylindroma)
10/2014
1Triple Negative Breast Neoplasms
10/2014
1Prostatic Neoplasms (Prostate Cancer)
12/2012
1Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
11/2010
1Carcinogenesis
08/2010

Drug/Important Bio-Agent (IBA)

3Biomarkers (Surrogate Marker)IBA
01/2020 - 10/2014
2DNA (Deoxyribonucleic Acid)IBA
11/2023 - 12/2018
2Poly(ADP-ribose) Polymerase InhibitorsIBA
11/2023 - 10/2021
2Estrogen ReceptorsIBA
12/2020 - 08/2016
2snake venom protein C activatorIBA
01/2020 - 11/2018
2LigandsIBA
01/2020 - 08/2010
2Proteolysis Targeting ChimeraIBA
01/2020 - 11/2018
2EverolimusFDA Link
08/2016 - 02/2015
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2016 - 07/2013
2SCH772984IBA
01/2016 - 07/2013
2AntibodiesIBA
08/2010 - 10/2006
1MethyltransferasesIBA
11/2023
1AZD5305IBA
11/2022
1olaparibIBA
11/2022
1Antisense OligonucleotidesIBA
01/2022
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
10/2021
1IndazolesIBA
12/2020
1danvatirsenIBA
12/2020
1osimertinibIBA
01/2020
1durvalumabIBA
01/2020
1compound 21IBA
01/2020
1AZD3229IBA
01/2020
1regorafenibIBA
01/2020
1Sunitinib (Sutent)FDA Link
01/2020
1Immune Checkpoint InhibitorsIBA
01/2020
1Adenosine (Adenocard)FDA LinkGeneric
01/2020
1Platelet-Derived Growth FactorIBA
01/2020
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
01/2020
1Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA
01/2020
1Drug CombinationsIBA
01/2019
1C-terminal binding proteinIBA
12/2018
1Proteins (Proteins, Gene)FDA Link
12/2018
1palbociclibIBA
08/2016
1VorinostatFDA Link
08/2016
1Fulvestrant (Faslodex)FDA Link
08/2016
1matrigelIBA
02/2015
1Estrogens (Estrogen)FDA Link
02/2015
1Mitogen-Activated Protein KinasesIBA
07/2013
1Phosphoric Monoester Hydrolases (Phosphatases)IBA
12/2012
1TensinsIBA
12/2012
1TOR Serine-Threonine KinasesIBA
12/2012
1MTOR InhibitorsIBA
12/2012
1Phosphatidylinositols (Phosphatidylinositol)IBA
12/2012
1PanobinostatIBA
11/2010
1Wnt ProteinsIBA
08/2010
1Therapeutic UsesIBA
08/2010
1beta CateninIBA
08/2010
1Lymphotoxin beta ReceptorIBA
10/2006
1Monoclonal AntibodiesIBA
10/2006

Therapy/Procedure

7Therapeutics
01/2021 - 10/2006
1Immunotherapy
01/2022